ERBB2 and prostate neoplasm: Moreover, recombinant humanized ERBB2 monoclonal antibody pertuzumab prevents dimerization of ERBB2 with EGFR and ERBB3 to prevent activation of downstream pathways, which is demonstrated to be inhibiting breast and prostate tumor growth78,80.